a Department of Pediatric Oncology and Hematology , University Children's Hospital Essen , Essen , Germany.
b Department of Pediatric Oncology and Hematology , Charité University Medicine , Berlin , Germany.
Expert Rev Mol Diagn. 2016 Dec;16(12):1307-1313. doi: 10.1080/14737159.2016.1256207. Epub 2016 Nov 15.
Neuroblastoma is a solid cancer of childhood, which is devastating upon recurrence. Markers for minimal residual disease and early detection of relapse are eagerly awaited to improve the outcome of affected patients. Several miRNAs have been identified as key regulators of neuroblastoma pathogenesis. Areas covered: Here, we focus on miRNAs that have been linked to MYCN, a prominent oncogenic driver, and we review the hitherto known interactions between miRNAs and other important players in neuroblastoma. Expert commentary: Existing diagnostic miRNA signatures remain to be established in clinical settings. Moreover, inhibition of individual oncogenic miRNAs or enhancement of tumor suppressive miRNA function could represent a new therapeutic approach in cancer treatment, including NB.
神经母细胞瘤是一种儿童实体癌，一旦复发就会造成严重后果。目前迫切需要用于微小残留病的标志物和复发的早期检测，以改善受影响患者的预后。已经发现了几种 microRNA，它们是神经母细胞瘤发病机制的关键调节剂。 涵盖领域：在这里，我们重点关注与 MYCN 相关的 microRNA，MYCN 是一个主要的致癌驱动因子，我们回顾了 microRNA 与神经母细胞瘤中其他重要参与者之间迄今已知的相互作用。 专家评论：现有的诊断 microRNA 特征仍有待在临床环境中建立。此外，抑制单个致癌 microRNA 或增强肿瘤抑制性 microRNA 功能可能代表癌症治疗中的一种新的治疗方法，包括 NB。
